National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Adalimumab (Humira®)

Economic evaluation of Adalimumab (Humira®) in combination with methotrexate for polyarticular juvenile idiopathic arthritis in children and adolescents (4-17yrs) in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.

Rapid Review

Commenced Completed Outcome
20/05/2011 02/06/2011 Full Pharmacoeconomic Evaluation not Recommended